Johnson & Johnson JNJ

$252.93 -3.10 (-1.21%)

Valuation

Market cap
617,006,144,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.82
Forward PE
22.42
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
10,032,700
Avg volume
6,795,742
Day's range
$252.51 – $256.24
Shares out
2,409,898,000
Stochastic %K
2%
Beta
0.21
Analysts
Strong Sell
Price target
$282.28

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

jbess22 Oct 6, 3:19 PM 0 replies
Wallstfan Oct 6, 2:58 PM
$JNJ added under $251.60. Been waiting for a dip
0 replies
yellowstar16 Oct 6, 1:46 PM
$JNJ oversold. Look for Green Day.
0 replies
kill3rnb1975 Oct 6, 11:41 AM
$JNJ Guys ILs companies with solid working tech, with proven results are worth over $1.X billion, so off rip PDSB should be worth $11.50. If the NIH and IBRX is messing with them and the original tech pass MRK hands, $1.20 is cheap. Mastering how to handle and boost Interleukins to fight cancers are always game changers. See IBRX, SLS, IOVA, etc. You're welcome!
0 replies
ElliottwaveForecast Oct 6, 1:14 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 replies
YGLD Oct 5, 10:58 PM
Pneumonic Plague 🦠 $JNJ $MRNA $DJI $BTC.X $SPY
0 replies
YGLD Oct 5, 10:40 PM
Big Pharma Watching A New Plague 100x Deadlier Than COVID Start Spreading $SPY $DJI $VIX $BTC.X $JNJ
2 replies
thatsolardude365 Oct 5, 9:13 PM
$JNJ talc litigation watch: roughly 68,000 cases remain pending in federal MDL 2738 over alleged links to ovarian and other cancers. Mediation continues but no global deal; lawsuits only, nothing to claim. Open Class Actions.
1 replies